Residential treatment for smokeless tobacco use: A case series
Received 6 September 2003; received in revised form 6 January 2004; accepted 27 January 2004.
Abstract
We developed and implemented a novel 8-day residential treatment program for smokeless tobacco (ST) use. A multidisciplinary team delivered behavioral treatment, nicotine patches were adjusted to achieve 100% replacement of baseline peak serum nicotine concentrations, and bupropion sustained-release was prescribed. Mean participant age (± SD) was 47.4 ± 18.2 years. Mean nicotine patch dose at program end was 43.2 mg/day ± 13.9 (range 14 to 66 mg/d). Median percent replacement by serum nicotine concentrations was 86.6% (IQR: 75–113.8%). At 1 year, the biochemically-confirmed (urine anabasine <2.0 ng/mL) self-reported 7-day point prevalence tobacco abstinence rate was 58% (14/24). A residential treatment program for ST users may be effective. More research is needed to replicate our findings and determine if comparable abstinence rates can be achieved with outpatient ST treatment programs using similar behavioral and pharmacotherapies.
aNicotine Dependence Center, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA
bDivision of Community Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA
cSection of Patient Education, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA
dDepartment of Psychiatry and Psychology, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA
eDepartment of Dental Specialties, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA
Corresponding author. Nicotine Dependence Center, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Tel.: +1-507-266-1944; fax: +1-507-266-7900
ABSTRACT